CAT-1004: Phase I/II started

Catabasis began the open-label, dose-escalation, U.S. Phase I/II MoveDMD trial to evaluate 3 dose levels of oral CAT-1004 for 7 days in about 18 ambulatory patients ages 4-7. Eligible patients will th...